Aims: The purpose of this study was to compare inpatient insulin needs with usual home insulin needs for severely insulin resistant individuals using U-500 insulin.
Methods: This was a retrospective review of patients using U-500 insulin at one institution. Subjects were divided into 3 groups according to their pre-admission HbA1c [<8%, 8-8.99%, ≥9%] as glycemic control could impact inpatient insulin requirements. The primary outcome was the average total daily insulin dose during hospitalization. Secondary outcomes included the degree of blood sugar control during hospitalizations and insulin doses 6 months after discharge.
Results: Sixty-three patients with a total of 116 admissions were included. The average inpatient insulin dose was only 22.6% of the usual home insulin dose. There were no differences in the frequency of low blood sugars between glycemic control groups. By 6-months post-discharge the majority of subjects were back on their pre-admission dosing.
Conclusions: Inpatient insulin needs were strikingly reduced (by average 75%) compared to home dosing regardless of pre-admission glycemic control. The results of this study should encourage institutions to assess their inpatient insulin protocols for U-500 using individuals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabres.2016.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Rates of Screening for Hypercortisolism Among Patients With Severe Insulin Resistance Requiring U-500 Insulin.
Endocr Pract
May 2024
Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Spontaneous Remission of Acquired Generalized Lipodystrophy Presenting in the Postpartum Period.
JCEM Case Rep
February 2024
Atlantic Medical Group, Atlantic Health System, Morristown, NJ 07960, USA.
Acquired generalized lipodystrophy (AGL) is a rare condition characterized by the diffuse loss of adipose tissue resulting in hyperglycemia, severe insulin resistance, and sequelae of metabolic disease. Here, we report the case of a 32-year-old woman who developed uncontrolled hyperglycemia and significant weight loss within 2 months postpartum. Upon endocrine evaluation, she was found to have generalized loss of adiposity, hypoleptinemia, and persistent hyperglycemia despite aggressive insulin administration.
View Article and Find Full Text PDFA simplified straightforward protocol for the use of U-500 regular insulin.
Diabetes Obes Metab
February 2023
Charles R. Drew University, Los Angeles, California, USA.
Glycemic Outcomes of Hospitalized Patients on Ambulatory Humulin-R U-500 Insulin.
Endocr Pract
December 2022
Division of Endocrinology, Diabetes, & Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:
Objective: Managing hospitalized patients on ambulatory U-500 insulin is challenging because of limited guidance on how to safely adjust insulin doses during admission. We sought to evaluate glycemic outcomes in relation to inpatient insulin doses in patients receiving U-500 prior to hospitalization.
Methods: Retrospective study of hospitalized patients on ambulatory U-500 seen consecutively from January 2015 to December 2019.
Introduction: Humulin R U-500 (U-500R) utilization has increased in the past few years, raising concerns as U-500R is indicated only for patients requiring > 200 units of insulin. Thus, evidence of dispensed total daily dose (dTDD) > 200 units of prior U-100 insulin based on pharmacy claims is increasingly used as a criterion to determine appropriate switching to U-500R by payers. The study compared the treatment patterns and outcomes before and after U-500R initiation among patients who were identified with ≤ 200 units/day U-100 insulin fill in order to understand the appropriateness of switching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!